Catalyst
Slingshot members are tracking this event:
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Additional Information
Under the CRADA, NCI will evaluate a novel TCR therapy candidate targeting HPV-16 E7 as a monotherapy and in combination with a checkpoint inhibitor in HPV-16 associated solid tumors. This Phase 1/2 clinical study will be led by Christian S. Hinrichs, M.D., from the ETIB and lead investigator of this CRADA. The NCI will also continue to advance a separately designed TCR therapy candidate targeting HPV-16 E6, currently in a Phase 1/2 clinical trial, under an existing CRADA between Kite and the Surgery Branch of the NCI, led by Steven A. Rosenberg, M.D., Ph.D.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
T-cell Receptor Therapy, Hpv-associated Cancer, Crada
